A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Endeavor Biomedicines, Inc.
Instituto do Cancer do Estado de São Paulo
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute
Novartis
National Cancer Institute (NCI)